PE20181377A1 - Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico - Google Patents

Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico

Info

Publication number
PE20181377A1
PE20181377A1 PE2018000972A PE2018000972A PE20181377A1 PE 20181377 A1 PE20181377 A1 PE 20181377A1 PE 2018000972 A PE2018000972 A PE 2018000972A PE 2018000972 A PE2018000972 A PE 2018000972A PE 20181377 A1 PE20181377 A1 PE 20181377A1
Authority
PE
Peru
Prior art keywords
corticosteroid
inhalation
anticholinergic
long
dry powder
Prior art date
Application number
PE2018000972A
Other languages
English (en)
Spanish (es)
Inventor
Claudio Cafiero
Leonardo Ortenzi
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181377(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PE20181377A1 publication Critical patent/PE20181377A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2018000972A 2015-11-16 2016-11-14 Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico PE20181377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15194661 2015-11-16

Publications (1)

Publication Number Publication Date
PE20181377A1 true PE20181377A1 (es) 2018-09-05

Family

ID=54548063

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000972A PE20181377A1 (es) 2015-11-16 2016-11-14 Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico

Country Status (31)

Country Link
US (3) US10086003B2 (enExample)
EP (2) EP3377109B1 (enExample)
JP (1) JP6942126B2 (enExample)
KR (1) KR20180082442A (enExample)
CN (1) CN108348614B (enExample)
AR (1) AR106687A1 (enExample)
AU (1) AU2016357988B2 (enExample)
CA (1) CA3005291C (enExample)
CL (1) CL2018001297A1 (enExample)
CO (1) CO2018005139A2 (enExample)
DK (2) DK3377109T3 (enExample)
EA (1) EA037346B1 (enExample)
ES (2) ES2789365T3 (enExample)
GE (2) GEP20207178B (enExample)
HR (2) HRP20211599T1 (enExample)
HU (2) HUE050343T2 (enExample)
IL (1) IL259327B (enExample)
MA (1) MA52437A (enExample)
MX (1) MX377113B (enExample)
MY (1) MY198321A (enExample)
PE (1) PE20181377A1 (enExample)
PH (1) PH12018501023A1 (enExample)
PL (2) PL3689379T3 (enExample)
PT (2) PT3689379T (enExample)
SA (1) SA518391574B1 (enExample)
SG (2) SG10201912090UA (enExample)
SI (2) SI3689379T1 (enExample)
TW (1) TWI729025B (enExample)
UA (1) UA125173C2 (enExample)
WO (1) WO2017085007A1 (enExample)
ZA (1) ZA201803167B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206619A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2018206618A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US11304901B2 (en) * 2019-08-28 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Liposome formulation of fluticasone furoate and method of preparation
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN117064869B (zh) * 2023-09-27 2026-05-12 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
RU2580312C2 (ru) 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
LT3019153T (lt) * 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba

Also Published As

Publication number Publication date
ES2789365T3 (es) 2020-10-26
GEAP201614782A (enExample) 2020-04-27
TW201722403A (zh) 2017-07-01
CA3005291A1 (en) 2017-05-26
UA125173C2 (uk) 2022-01-26
SI3377109T1 (sl) 2020-07-31
WO2017085007A1 (en) 2017-05-26
AU2016357988B2 (en) 2021-12-16
BR112018009811A8 (pt) 2019-02-26
US10959944B2 (en) 2021-03-30
MX2018005979A (es) 2018-08-29
SI3689379T1 (sl) 2021-11-30
TWI729025B (zh) 2021-06-01
PH12018501023B1 (en) 2018-12-17
EP3377109A1 (en) 2018-09-26
JP6942126B2 (ja) 2021-09-29
HUE056402T2 (hu) 2022-02-28
CA3005291C (en) 2024-01-16
PT3689379T (pt) 2021-09-24
DK3689379T3 (da) 2021-09-06
KR20180082442A (ko) 2018-07-18
MA52437A (fr) 2021-05-05
CN108348614A (zh) 2018-07-31
PL3377109T3 (pl) 2020-09-21
GEP20207178B (en) 2020-11-10
US10786451B2 (en) 2020-09-29
PT3377109T (pt) 2020-05-13
AR106687A1 (es) 2018-02-07
AU2016357988A1 (en) 2018-05-31
ES2890409T3 (es) 2022-01-19
HUE050343T2 (hu) 2020-11-30
US10086003B2 (en) 2018-10-02
IL259327B (en) 2020-11-30
HRP20211599T1 (hr) 2022-01-07
PH12018501023A1 (en) 2018-12-17
EP3689379A1 (en) 2020-08-05
HK1256859A1 (zh) 2019-10-04
EP3377109B1 (en) 2020-03-04
EA037346B1 (ru) 2021-03-16
JP2018537453A (ja) 2018-12-20
EA201890967A1 (ru) 2018-12-28
MX377113B (es) 2025-03-07
SA518391574B1 (ar) 2021-06-13
HRP20200571T1 (hr) 2020-07-10
US20200360278A1 (en) 2020-11-19
BR112018009811A2 (pt) 2018-11-13
EP3689379B1 (en) 2021-08-11
CL2018001297A1 (es) 2018-08-10
NZ742473A (en) 2024-11-29
PL3689379T3 (pl) 2021-12-13
CO2018005139A2 (es) 2018-08-10
IL259327A (en) 2018-07-31
US20190021994A1 (en) 2019-01-24
CN108348614B (zh) 2021-09-21
MY198321A (en) 2023-08-24
GEAP202014782A (en) 2020-04-27
DK3377109T3 (da) 2020-04-20
SG10201912090UA (en) 2020-02-27
US20170136034A1 (en) 2017-05-18
ZA201803167B (en) 2019-07-31
SG11201804048WA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
PE20181488A1 (es) Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
TN2017000226A1 (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
AR129501A2 (es) FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN
RU2015100905A (ru) Сухой порошок для ингаляционного препарата, включающий сальметерола ксинафоат, флутиказона пропионат и тиотропия бромид, а также способ его изготовления
BR112018009644A2 (pt) micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
PE20180522A1 (es) Unidad de dosificacion orodispersable que contiene un componente estetrol
RU2014140539A (ru) Агрегированные частицы
JP2014224147A5 (enExample)
IL251413B1 (en) Composition of injectable buprenorphine
PE20141703A1 (es) Formulacion seca en polvo que comprende un corticoesteroide y un beta-adrenergico para administrar por inhalacion
GEAP202014782A (en) Process for preparing dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
MX392381B (es) Formulacion de anestesico local de duracion prolongada
MX2015012529A (es) Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla.
PH12019500059A1 (en) A pharmaceutical formulation for oral administration with improved content uniformity comprising sustained-release containing tamsulosin hydrochloride
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
MX2019012931A (es) Proceso para preparar una formulacion de polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.
RU2017103751A (ru) Тонкодисперсный инсулин, тонкодисперсные аналоги инсулина и спсобы их промышленного получения
MX374484B (es) Proceso para preparacion de una formulacion de polvo seco que incluye un anticolinergico, un corticosteroide y un beta-adrenergico.
EA201700183A1 (ru) Лекарственный препарат, содержащий будесонид и формотерол
TH159392A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด
Leach et al. A46 OCCUPATION, OBESITY, AND LUNG HEALTH: Nonclinical Safety Of An Inhaled Spray-Dried Porous Particle Excipient For Drug Delivery Via Metered Dose Inhalers
AR096878A1 (es) FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO PARA ADMINISTRAR POR INHALACIÓN
UA95689U (uk) Спосіб одержання супозиторної форми лікарського засобу для терапії захворювань передміхурової залози